Drug and asset intelligence for Tovorafenib (DAY101) with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Stage: Development stage unavailable

Recent signals(1)

ClinicalAugust 11, 2026

Phase II Trial of Tovorafenib (DAY101) for Relapsed/Refractory Langerhans Cell Histiocytosis

A phase II trial is currently evaluating the safety, tolerability, and efficacy of tovorafenib (DAY101) in patients with progressive, relapsed, or refractory Langerhans cell histiocytosis.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Hematology →

Langerhans Cell Histiocytosis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.